Trial Search Results
Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome
The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.
Stanford is currently not accepting patients for this trial.
NICHD Neonatal Research Network
- Drug: Exosurf
- Drug: Survanta
Phase 2/Phase 3
- Newborn infants weighing 501 to 1500 gm with respiratory distress syndrome were
receiving assisted ventilation with 30% oxygen or more
- Less than 6 hours of age
Ages Eligible for Study
N/A - 6 Hours
Genders Eligible for Study